TerminatedPhase 2NCT04411082
A Study of IMR-687 in Subjects With Beta Thalassemia
Studying Beta-thalassemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Cardurion Pharmaceuticals, Inc.
- Principal Investigator
- Steve LuperchioCardurion Pharmaceuticals
- Intervention
- IMR-687(drug)
- Enrollment
- 122 enrolled
- Eligibility
- 18-65 years · All sexes
- Timeline
- 2020 – 2022
Study locations (30)
- Herlev Hospital, Herlev, Capital Region, Denmark
- Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, Haute-Garonn, France
- Hôpital Edouard Herriot, Lyon, Rhone, France
- Hôpital Necker-Enfants Malades, Paris, France
- M. Zodelava Hematology Centre, Tbilisi, Borjomi, Georgia
- National Center of Surgery, Tbilisi, Georgia
- Medinvest - Institute of Hematology and Transfusiology, Tbilisi, Georgia
- Aghia Sofia General Children's Hospital, Athens, Attica, Greece
- Laiko General Hospital of Athens, Athens, Attica, Greece
- Ippokrateio General Hospital of Thessaloniki, Thessaloniki, Central Macedonia, Greece
- University General Hospital of Patras, Patra, Peloponnese, Greece
- Rambam Health Care Campus, Haifa, Haifa District, Israel
- Hadassah University Hospital Ein Kerem, Jerusalem, Jerusalem, Israel
- The Galilee Medical Center, Nahariya, Northern District, Israel
- Emek Medical Center, Afula, Israel
- +15 more locations on ClinicalTrials.gov
Collaborators
Imara, Inc.
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04411082 on ClinicalTrials.govOther trials for Beta-thalassemia
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07215975A Real-World Study to Evaluate Luspatercept in Adults With Transfusion-Dependent Beta-Thalassemia in the Middle EastBristol-Myers Squibb
- ENROLLING BY INVITATIONNCT07055503Use of the Hemanext One® Hypoxic Red Blood Cell Storage System for Transfusion in Thalassemia PatientsUniversity Research Institute for the Study of Genetic & Malignant Disorders in Childhood
- RECRUITINGNANCT07207577Evaluation of Physiological and Psychological Factors Involved in Exercise Intolerance in Patients With β-TTDCentre Hospitalier Metropole Savoie
- ENROLLING BY INVITATIONNCT06717932A Follow-up Study to Evaluate the Long-term Safety and Efficacy in Participants Who Received CS-101 InjectionCorrectSequence Therapeutics Co., Ltd
- RECRUITINGPHASE1, PHASE2NCT06364774ALS20-101 Lentiviral Gene Therapy for Beta ThalassemiaChildren's Hospital of Philadelphia
- ENROLLING BY INVITATIONNCT06685536A Long-term Follow-up Study in Participants Who Received CS-101CorrectSequence Therapeutics Co., Ltd
- RECRUITINGPHASE1NCT06772766A Multiple Ascending Dose Study of 9MW3011 in Patients With Non-transfusion-dependent β-thalassemiaMabwell (Shanghai) Bioscience Co., Ltd.
- RECRUITINGNANCT06734520Clinical Study of Super Transplantation in the Treatment of Severe β-thalassemiaGuangzhou Women and Children's Medical Center